

RealRate

PHARMACEUTICAL 2019

Ra Pharmaceuticals Inc. Rank 39 of 363









Ra Pharmaceuticals Inc. Rank 39 of 363

The relative strengths and weaknesses of Ra Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ra Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Ra Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 252%, being 215% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	212,407
Cost of Goods Sold	0
Intangible Assets	314
Liabilities, Current	10,201
Liabilities, Non-Current	0
Other Assets	1,334
Other Compr. Net Income	0
Other Expenses	-19
Other Liabilities	1,901
Other Net Income	1,426
Other Revenues	2,500
Property and Equipment	5,165
Research and Development	54,449
Selling, General and Administrative Expense	14,439

Output Variable	Value in 1000 USD
Assets	219,220
Liabilities	12,102
Expenses	68,869
Revenues	2,500
Stockholders Equity	207,118
Net Income	-64,943
Comprehensive Net Income	-64,943
Economic Capital Ratio	252%

